<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033657</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069309</org_study_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E1201</secondary_id>
    <nct_id>NCT00033657</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer</brief_title>
  <official_title>Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
      die. Combining radiation therapy with chemotherapy before and after surgery may kill more
      tumor cells.

      PURPOSE: Randomized phase II trial to compare the effectiveness of combining radiation
      therapy with two different chemotherapy regimens before and after surgery in treating
      patients who have esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the pathologic complete response rate in patients with adenocarcinoma of the
           esophagus or gastroesophageal junction treated with radiotherapy with pre- and
           post-operative cisplatin plus paclitaxel versus cisplatin plus irinotecan.

        -  Compare the survival outcome in patients treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the tolerability of these adjuvant chemotherapy regimens after neoadjuvant
           chemoradiotherapy in these patients.

        -  Compare time to progression or recurrence in patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG
      performance status (0 vs. 1) and stage of disease (T2-3, N0, M0 vs. T1-3, N0-1, M0 or M1A).
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm A: Patients receive neoadjuvant radiotherapy once daily, 5 days a week, for 5 weeks
           beginning on day 1 concurrently with neoadjuvant chemotherapy comprising cisplatin IV
           (Intravenous) over 2-3 hours followed by irinotecan IV over 30-60 minutes once daily on
           days 1, 8, 22, and 29. Four to six weeks after completion of neoadjuvant
           chemoradiotherapy, patients undergo surgical resection. A minimum of 4 weeks after
           resection, patients receive adjuvant chemotherapy comprising cisplatin and irinotecan as
           above on days 1 and 8. Treatment with adjuvant chemotherapy repeats every 3 weeks for 3
           courses.

        -  Arm B: Patients receive neoadjuvant radiotherapy as in arm A concurrently with
           neoadjuvant chemotherapy comprising paclitaxel IV (Intravenous) over 1 hour followed by
           cisplatin IV over 2-3 hours once daily on days 1, 8, 15, 22, and 29. Patients then
           undergo surgical resection as in arm A. A minimum of 4 weeks after resection, patients
           receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours followed by
           cisplatin as above on day 1. Treatment with adjuvant chemotherapy repeats every 3 weeks
           for 3 courses.

      In both arms, treatment continues in the absence of disease progression or unacceptable
      toxicity.

      Patients are followed at 1 month, every 3 months for 2 years, every 6 months for 3 years, and
      then annually for 5 years.

      ACCRUAL: A total of 97 patients (50 on Arm A and 47 on Arm B) were accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
    <description>A patient would have achieved a pathologic complete response if no histopathological evidence of residual tumor is found in the resected esophageal specimen and nodal tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>Approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
    <description>Survival was measured from the date of randomization onto study to death from any cause.Patients who were still alive at the end of the study were censored at the last date of known alive. Median survival time was calculated in the 81 eligible and treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival Time</measure>
    <time_frame>Approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
    <description>Recurrence-free survival is measured from the date of complete response to recurrence of the cancer. Patients without recurrence were censored at the last date of known recurrence-free. Median recurrence-free survival time was calculated in the eligible and treated patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin / Irinotecan / Radiation therapy (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel / Cisplatin / Radiation therapy (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29
Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
    <arm_group_label>Cisplatin / Irinotecan / Radiation therapy (Arm A)</arm_group_label>
    <arm_group_label>Paclitaxel / Cisplatin / Radiation therapy (Arm B)</arm_group_label>
    <other_name>cis-platinum</other_name>
    <other_name>platinum</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>DDP</other_name>
    <other_name>CDDP</other_name>
    <other_name>DACP</other_name>
    <other_name>NSC 119875</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29
Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
    <arm_group_label>Cisplatin / Irinotecan / Radiation therapy (Arm A)</arm_group_label>
    <other_name>Camptothecin-11</other_name>
    <other_name>CPT-11</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29
Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles</description>
    <arm_group_label>Paclitaxel / Cisplatin / Radiation therapy (Arm B)</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>NSC 125973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.</description>
    <arm_group_label>Cisplatin / Irinotecan / Radiation therapy (Arm A)</arm_group_label>
    <arm_group_label>Paclitaxel / Cisplatin / Radiation therapy (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.</description>
    <arm_group_label>Cisplatin / Irinotecan / Radiation therapy (Arm A)</arm_group_label>
    <arm_group_label>Paclitaxel / Cisplatin / Radiation therapy (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed adenocarcinoma of the esophagus (20 cm below incisors) or
             gastroesophageal junction

               -  Stage T2-3, N0, M0 OR

               -  Stage T1-3, N0-1, M0 or M1A (celiac nodal metastasis)

          -  Tumor must be considered surgically resectable (T1-3, but not T4)

          -  Age&gt;=18 years

          -  ECOG Performance status 0-1

          -  Adequate hematopoietic, hepatic, renal functions defined by the following within 4
             weeks prior to randomization:

          -  Granulocyte count at least 1,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 mg/dL

          -  Creatinine clearance at least 60 mL/min

          -  Prior curatively treated malignancy allowed if currently disease-free and survival
             prognosis is more than 5 years

          -  Fertile patients must use effective contraception

          -  Endoscopy with biopsy and dilation allowed

        Exclusion Criteria:

          -  Tumor extends more than 2 cm into the cardia

          -  Pregnant or nursing

          -  Other concurrent illness that would preclude study therapy or surgical resection

          -  Concurrent filgrastim (G-CSF) during study radiotherapy

          -  Prior chemotherapy

          -  Prior radiotherapy

          -  Prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Kleinberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program, Incorporated</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Cancer Center at the University of Florida Health Science Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-100277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Lakeside Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-4494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth's Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MainLine Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kleinberg L, Powell ME, Forastiere AA, et al.: Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. [Abstract] J Clin Oncol 26 (Suppl15): A-4532, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Kleinberg LR, Eapen S, Hamilton S, et al.: E1201: an Eastern Cooperative Oncology Group (ECOG) randomized phase II trial to measure response rate and toxicity of preoperative combined modality paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in adenocarcinoma of the esophagus. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-143, S80, 2006.</citation>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>June 21, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2011</results_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>E1201 opened to accrual on May 21, 2002 and accrued its first patient on August 15, 2002. A total of 97 patients were accrued from 19 different participating sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cisplatin / Irinotecan / RT (Arm A)</title>
          <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
        </group>
        <group group_id="P2">
          <title>Paclitaxel / Cisplatin / RT (Arm B)</title>
          <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Neoadjuvant Chemotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Treated</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not started protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Surgical Resection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not complete resection</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Adjuvant Chemotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cisplatin / Irinotecan / RT (Arm A)</title>
          <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel / Cisplatin / RT (Arm B)</title>
          <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="9.7"/>
                    <measurement group_id="B2" value="59.9" spread="10.7"/>
                    <measurement group_id="B3" value="58.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>A patient would have achieved a pathologic complete response if no histopathological evidence of residual tumor is found in the resected esophageal specimen and nodal tissue.</description>
        <time_frame>approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
        <population>Eligible, treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin / Irinotecan / RT (Arm A)</title>
            <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel / Cisplatin / RT (Arm B)</title>
            <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate</title>
          <description>A patient would have achieved a pathologic complete response if no histopathological evidence of residual tumor is found in the resected esophageal specimen and nodal tissue.</description>
          <population>Eligible, treated patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="6.9" upper_limit="28.1"/>
                    <measurement group_id="O2" value="16.7" lower_limit="8.1" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time</title>
        <description>Survival was measured from the date of randomization onto study to death from any cause.Patients who were still alive at the end of the study were censored at the last date of known alive. Median survival time was calculated in the 81 eligible and treated patients.</description>
        <time_frame>Approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
        <population>Eligible, treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin / Irinotecan / RT (Arm A)</title>
            <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel / Cisplatin / RT (Arm B)</title>
            <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time</title>
          <description>Survival was measured from the date of randomization onto study to death from any cause.Patients who were still alive at the end of the study were censored at the last date of known alive. Median survival time was calculated in the 81 eligible and treated patients.</description>
          <population>Eligible, treated patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="19.5" upper_limit="67.7"/>
                    <measurement group_id="O2" value="21.0" lower_limit="17.4" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Survival Time</title>
        <description>Recurrence-free survival is measured from the date of complete response to recurrence of the cancer. Patients without recurrence were censored at the last date of known recurrence-free. Median recurrence-free survival time was calculated in the eligible and treated patients.</description>
        <time_frame>Approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin / Irinotecan / RT (Arm A)</title>
            <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel / Cisplatin / RT (Arm B)</title>
            <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival Time</title>
          <description>Recurrence-free survival is measured from the date of complete response to recurrence of the cancer. Patients without recurrence were censored at the last date of known recurrence-free. Median recurrence-free survival time was calculated in the eligible and treated patients.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="13.3">The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                    <measurement group_id="O2" value="12.4" lower_limit="11.0" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported 4-6 weeks after the end of pre-op chemotherapy/RT, (just prior to resection) and 4 weeks after the end of adjuvant chemotherapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant_Cisplatin / Irinotecan / RT (Arm A)</title>
          <description>Days 1 - 35 : Concurrent radiation therapy and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles</description>
        </group>
        <group group_id="E2">
          <title>Neoadjuvant_Paclitaxel / Cisplatin / RT (Arm B)</title>
          <description>Days 1 - 35 : Concurrent RT and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.</description>
        </group>
        <group group_id="E3">
          <title>Adjuvant_Cisplatin / Irinotecan / RT ( Arm A)</title>
          <description>Adjuvant chemotherapy toxicities in treated patients</description>
        </group>
        <group group_id="E4">
          <title>Adjuvant_Paclitaxel / Irinotecan / RT ( Arm B)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion:PRBCS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dysphagia-esophageal radiation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis due to radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain due to radiation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia-pharyngeal radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary electrolyte wasting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear/hearing imparied</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abonominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia-esophageal radiation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia-pharyngeal radiation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>Eastern Cooperative Oncology Group (ECOG) Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

